ClinicalTrials.gg
TerminatedNCT06222034Updated Jul 15, 2026

Study to Measure Filgotinib in the Blood of Children and Teenagers With Arthritis Taking Filgotinib (SCALESIA)

A Phase 1 interventional study of Filgotinib and Filgotinib in Juvenile Idiopathic Arthritis, sponsored by Alfasigma S.p.A.. Terminated at 10 sites in 5 countries. Open to participants aged 8 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by Alfasigma S.p.A. · Phase 1, Interventional, and Treatment

Why this study was terminated
The sponsor decided to stop recruitment and to early terminate the trial with 9 enrolled patients.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Non-randomized
Ages
8 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 53 studies in Arthritis, Juvenile with a site in Germany — 14 open to participants now, 17 under way, 11 of them phase 3. Arthritis, Juvenile · Germany.

Enrollment
44th of 45
9 · median 86
Started
2024
with 2 others
Phase 1
7 of 53
none open now
Registered
45th of 53
by date
Lead sponsor
3 of 53
Alfasigma S.p.A.

Among the 53 studies in Arthritis, Juvenile with a site in Germany, this one is the 44th largest by enrollment of the 45 interventional ones that give a count, is one of 3 that started in 2024, is one of 7 in phase 1, and was the 45th registered.

Arthritis, Juvenile

366 studies on the registry are indexed under Arthritis, Juvenile; 102 are open to participants now.

Browse Arthritis, Juvenile studies →

Open to participants now

14 of the 53 studies in Arthritis, Juvenile with a site in Germany are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.

This study: 8 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Arthritis, Juvenile with a site in Germany, or all of them as a file.
02

Study summary

A Study to evaluate the pharmacokinetics, safety, and tolerability in paediatric population for treating juvenile idiopathic arthritis (JIA).

03

Conditions studied

  • Juvenile Idiopathic Arthritis

Browse trials for

04

Who can participate

Ages eligible
8 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participant with a (BMI) within the 5th to 95th percentiles for the age and gender (based on World Health Organization BMI charts). Participant must have a minimum weight of 15 kg.
  • Participant must meet the International League of Associations for Rheumatology classification for 1 of the following categories and have, according to the investigator's judgment, moderately to severely active disease that is not adequately controlled with his/her current therapy.

    • Rheumatoid factor (RF)-positive polyarthritis
    • RF-negative polyarthritis
    • Oligoarthritis
    • Psoriatic arthritis
    • Enthesis-related arthritis (ERA) Note: Historical Human leukocyte antigen B-27 (HLA-B27) results are considered appropriate for ERA diagnosis during screening.
    • Systemic JIA with active arthritis without active systemic features, or with active systemic features that are stable in the prior 6 months of time of enrollment
  • Participant with intolerance or a history of inadequate response to at least one of the following medications for the treatment of JIA, administered for at least 12 weeks, based on current treatment guidelines: conventional synthetic disease-modifying antirheumatic drugs and biological disease-modifying antirheumatic drugs (including methotrexate) and non-steroidal anti-inflammatory drugs for ERA and psoriatic arthritis.
  • Female participants of (i.e. who have passed menarche) must have a negative highly sensitive urine pregnancy test.

Key Exclusion Criteria:

  • Participant with persistent oligoarthritis.
  • Participant with undifferentiated arthritis.
  • Participant with any other any other rheumatic, inflammatory, or immunologic disease (e.g. inflammatory bowel disease, hypogammaglobulinemia, systemic lupus erythematosus, or uncontrolled uveitis).
  • Active infection that is , as per judgment of the investigator.
  • Participant with a history of complicated herpes zoster infection (with multi-dermatomal, disseminated, ophthalmic, or central nervous system involvement).
  • Currently on any therapy for chronic infection (such as pneumocystis, cytomegalovirus, herpes simplex, or atypical mycobacteria).

Note: Other protocol defined Inclusion/ Exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    Filgotinib Dose A

    Dose A of filgotinib mini-tablet for participants with bodyweight (BW) 15-\<25 kg

    Drug: Filgotinib

  • Experimental
    Filgotinib Dose B

    Dose B of filgotinib tablet for participants with BW ≥25-\<60 kg

    Drug: Filgotinib

  • Experimental
    Filgotinib Dose C

    Dose C of filgotinib tablet for participants with BW ≥60 kg

    Drug: Filgotinib

Interventions

  • Film-coated mini-tablets administered orally once daily

    Also known as: GS-6034, GLPG0634

  • Commercially developed film-coated tablet administered orally once daily

    Also known as: GS-6034, GLPG0634, Jyseleca

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration at steady state of filgotinib (Cmax,ss)

    Time frame: Pre-dose on Day 10, 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 8 hours post-dose on Day 10

  2. Cmax,ss of GS-829845, major active metabolite

    Time frame: Pre-dose on Day 10, 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 8 hours post-dose on Day 10

  3. Area under the plasma concentration-time curve over the dosing interval at steady state of filgotinib (AUC0-24,ss)

    Time frame: Pre-dose on Day 10, 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 8 hours post-dose on Day 10

  4. AUC0-24,ss of GS-829845, major active metabolite

    Time frame: Pre-dose on Day 10, 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 8 hours post-dose on Day 10

  5. Area under the plasma concentration time curve over the dosing interval at steady state or the effective exposure of filgotinib (AUCeff,ss)

    Time frame: Pre-dose on Day 10, 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 8 hours post-dose on Day 10

  6. AUCeff,ss of GS-829845, major active metabolite

    Time frame: Pre-dose on Day 10, 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 8 hours post-dose on Day 10

Secondary outcomes

  1. Number of participants with treatment-emergent adverse events (TEAEs), TEAEs of interest, serious TEAEs, and TEAEs leading to treatment discontinuation.

    Time frame: Baseline (Day 1) up to week 96

  2. Acceptability of the commercially developed film-coated tablets and of the minitablets as measured by the Pediatric Oral Medicine Acceptability Questionnaire for Patients (POMAQ-P).

    Time frame: Week 4 and week 12

07

Study locations

10 sites
  • CHU Amiens - Hopital Nord
    Amiens, 80054, France
  • Bicêtre University Hospital
    Le Kremlin-Bicêtre, 94270, France
  • Children's university hospital Charité, Campus Virchow, SPZ
    Berlin, 13353, Germany
  • Hamburger Zentrum fur Kinder und Jugendrheumatologie
    Hamburg, 22081, Germany
  • Asklepios Klinik Sankt Augustin GmbH
    Sankt Augustin, 53757, Germany
  • Malopolskie Badania Kliniczne
    Krakow, 30-002, Poland
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Sant Joan de Deu
    Barcelona, 08950, Spain
  • Hospital Universitari i Politecnic La Fe
    Valencia, 46026, Spain
  • Great Ormond Street Hospital
    London, WC1N 3JH, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2024 to primary completion in Jun 2026, 25 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2024
First posted
Jan 24, 2024
StartActual
May 13, 2024
Primary completionActual
Jun 17, 2026
CompletionActual
Jun 17, 2026
Last update
Jul 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06222034
Lead sponsor
Alfasigma S.p.A.
Responsible party
Sponsor
First posted
Jan 24, 2024
Start date
May 13, 2024
Primary completion
Jun 17, 2026
Completion
Jun 17, 2026
Last update
Jul 15, 2026

Study contacts

Alfasigma Study Director
study director · Alfasigma S.p.A.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GLPG0634

Start the discussion